- Home
- GH vs CROX Comparison
GH vs CROX Comparison
Compare GH & CROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- CROX
- Stock Information
- Founded
- GH 2011
- CROX 1999
- Country
- GH United States
- CROX United States
- Employees
- GH N/A
- CROX N/A
- Industry
- GH Medical Specialities
- CROX Shoe Manufacturing
- Sector
- GH Health Care
- CROX Consumer Discretionary
- Exchange
- GH Nasdaq
- CROX Nasdaq
- Market Cap
- GH 5.5B
- CROX 5.4B
- IPO Year
- GH 2018
- CROX 2006
- Fundamental
- Price
- GH $41.72
- CROX $109.77
- Analyst Decision
- GH Strong Buy
- CROX Strong Buy
- Analyst Count
- GH 21
- CROX 12
- Target Price
- GH $52.81
- CROX $133.45
- AVG Volume (30 Days)
- GH 2.7M
- CROX 1.7M
- Earning Date
- GH 04-30-2025
- CROX 05-08-2025
- Dividend Yield
- GH N/A
- CROX N/A
- EPS Growth
- GH N/A
- CROX 26.25
- EPS
- GH N/A
- CROX 16.31
- Revenue
- GH $773,996,000.00
- CROX $4,100,808,000.00
- Revenue This Year
- GH $19.53
- CROX $3.65
- Revenue Next Year
- GH $21.92
- CROX $3.39
- P/E Ratio
- GH N/A
- CROX $6.78
- Revenue Growth
- GH 28.20
- CROX 2.09
- 52 Week Low
- GH $18.01
- CROX $86.11
- 52 Week High
- GH $52.92
- CROX $165.32
- Technical
- Relative Strength Index (RSI)
- GH 43.79
- CROX 63.68
- Support Level
- GH $38.86
- CROX $98.14
- Resistance Level
- GH $52.92
- CROX $112.69
- Average True Range (ATR)
- GH 2.91
- CROX 3.75
- MACD
- GH -0.74
- CROX 1.93
- Stochastic Oscillator
- GH 20.34
- CROX 86.84
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.